Combination AZD5363 with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models

European Urology

Volumn 67, Issue 6, 2015, Pages 986-990

  Toren, Paul ^a   Kim, Soojin ^a   Cordonnier, Thomas ^a   Crafter, Claire ^b   Davies, Barry R ^b   Fazli, Ladan ^a   Gleave, Martin E ^a   Zoubeidi, Amina ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Akt inhibitor; Apoptosis; Enzalutamide; Prostate cancer

Indexed keywords

4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; ANDROGEN RECEPTOR; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; 4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; LNCAP CELL LINE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; HUMAN; METABOLISM; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929025574     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.08.006     Document Type: Article

References (10)

1. R.L. Bitting, and A.J. Armstrong Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer Endocr Relat Cancer 20 2013 R83 R99
2. B.S. Carver, C. Chapinski, and J. Wongvipat Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 2011 575 586
3. D.J. Mulholland, L.M. Tran, and Y. Li Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth Cancer Cell 19 2011 792 804
4. K.G. Chee, J. Longmate, and D.I. Quinn The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial Clin Genitourin Cancer 5 2007 433 437
5. B.R. Davies, H. Greenwood, and P. Dudley Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background Mol Cancer Ther 11 2012 873 887
6. H. Kuruma, H. Matsumoto, and M. Shiota A novel antiandrogen, compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo Mol Cancer Ther 12 2013 567 576
7. M. Korpal, J.M. Korn, and X. Gao An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) Cancer Discov 3 2013 1030 1043
8. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
9. C. Thomas, F. Lamoureux, and C. Crafter Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo Mol Cancer Ther 12 2013 2342 2355
10. C. Sweeney, Y. Chen, and M. Carducci Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial [abstract LBA2] J Clin Oncol 2014 32